TIF1-gamma IgG2 Isotype is Not Associated with Malignancy in Juvenile Dermatomyositis Patients
Overview
Overview
Journal
Rheumatology (Oxford)
Publisher
Oxford University Press
Specialty
Rheumatology
Date
2024 Mar 18
PMID
38498839
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
An update on autoantibodies in the idiopathic inflammatory myopathies.
Allameen N, Ramos-Lisbona A, Wedderburn L, Lundberg I, Isenberg D Nat Rev Rheumatol. 2024; 21(1):46-62.
PMID: 39609638 DOI: 10.1038/s41584-024-01188-4.
References
1.
Hinze C, Oommen P, Dressler F, Urban A, Weller-Heinemann F, Speth F
. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol Online J. 2018; 16(1):40.
PMC: 6019723.
DOI: 10.1186/s12969-018-0257-6.
View
2.
Cordel N, Dechelotte B, Jouen F, Lamb J, Chinoy H, New P
. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Rheumatology (Oxford). 2022; 62(4):1711-1715.
DOI: 10.1093/rheumatology/keac577.
View
3.
Yasin S, Schutz P, Deakin C, Sag E, Varsani H, Simou S
. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol. 2018; 45(5):495-512.
PMC: 6767402.
DOI: 10.1111/nan.12528.
View
4.
Papadopoulou C, Chew C, Wilkinson M, McCann L, Wedderburn L
. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023; 19(6):343-362.
PMC: 10184643.
DOI: 10.1038/s41584-023-00967-9.
View
5.
Tansley S, Simou S, Shaddick G, Betteridge Z, Almeida B, Gunawardena H
. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017; 84:55-64.
PMC: 5656106.
DOI: 10.1016/j.jaut.2017.06.007.
View